Efficacy and Safety of Low-dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2012 Dec 22

PMID 23258976

Authors

Zehui Yan

Ke Fan

Xiaohong Wang

Qing Mao

Guohong Deng

Yuming Wang

Affiliations

Soon will be listed here.

Abstract

Background. The purpose of this study was to assess the efficacy and safety of low-dose peg-IFN α-2a plus ribavirin on the treatment of patients with chronic hepatitis C virus (HCV) infection. Patients and Methods. A total of 243 HCV patients treated with different doses of peg-IFN α-2a plus ribavirin were stratified into three groups. End-of-treatment response (ETR) and sustained viral response (SVR) were evaluated for efficacy. Adverse events and laboratory abnormalities were conducted for safety. Results. ETR and SVR in group I were obtained in 83.9% and 68.9% of the patients, separately, which was similar to groups II (84.1% and 68.3%) and III (81.7% and 66.7%). The received peg-IFN α-2a dose was not the independent factor-related SVR in our population (OR, 1.31; 95% CI, 0.94-1.81; P = 0.106). The frequency of no adverse events reported in group III (24.7%) was significantly higher than that in group I (11.5%) and group II (12.7%) (P = 0.036). Conclusions. The peg-IFN α-2a 90 μg/week plus ribavirin is as effective as, and better tolerated than, peg-IFN α-2a standard dose with ribavirin in the treatment of chronic hepatitis C. This low-dose combination achieves high SVR rates and may be cost-saving.

References

Zeuzem S . Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med. 2004; 140(5):370-81. DOI: 10.7326/0003-4819-140-5-200403020-00033. View

Zeuzem S, Feinman S, Rasenack J, Heathcote E, Lai M, Gane E . Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343(23):1666-72. DOI: 10.1056/NEJM200012073432301. View

Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. DOI: 10.1038/nature08309. View

Ferenci P . Optimal treatment duration for patients with HCV genotype 1 infection. J Viral Hepat. 2012; 19 Suppl 1:7-13. DOI: 10.1111/j.1365-2893.2011.01522.x. View

Popkin B, Paeratakul S, Ge K, Zhai F . Body weight patterns among the Chinese: results from the 1989 and 1991 China Health and Nutrition Surveys. Am J Public Health. 1995; 85(5):690-4. PMC: 1615408. DOI: 10.2105/ajph.85.5.690. View

Manns M, Wedemeyer H, Cornberg M . Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55(9):1350-9. PMC: 1860034. DOI: 10.1136/gut.2005.076646. View

Meyer-Wyss B, Rich P, Egger H, Helbling B, Mullhaupt B, Rammert C . Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat. 2006; 13(7):457-65. DOI: 10.1111/j.1365-2893.2005.00709.x. View

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

10.

Ascione A, De Luca M, Tartaglione M, Lampasi F, Di Costanzo G, Lanza A . Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2009; 138(1):116-22. DOI: 10.1053/j.gastro.2009.10.005. View

11.

Sokal E, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010; 52(6):827-31. DOI: 10.1016/j.jhep.2010.01.028. View

12.

Liao X, Ling Y, Li X, Han Y, Zhang S, Gu L . Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther. 2011; 16(2):141-7. DOI: 10.3851/IMP1703. View

13.

Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P . Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011; 56(10):3024-31. DOI: 10.1007/s10620-011-1802-z. View

14.

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K . Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat. 2009; 16(8):578-85. DOI: 10.1111/j.1365-2893.2009.01116.x. View

15.

Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz M, Alric L, Samuel D . Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol. 2010; 9(3):242-8. DOI: 10.1016/j.cgh.2010.10.018. View

16.

Gupta R, Ramakrishna C, Lakhtakia S, Tandan M, Banerjee R, Reddy D . Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. World J Gastroenterol. 2006; 12(34):5554-6. PMC: 4088244. DOI: 10.3748/wjg.v12.i34.5554. View

17.

Sood A, Midha V, Hissar S, Kumar M, Suneetha P, Bansal M . Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol. 2007; 23(2):203-7. DOI: 10.1111/j.1440-1746.2007.05057.x. View

18.

McCombs J, Yuan Y, Shin J, Saab S . Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011; 33(9):1268-80. DOI: 10.1016/j.clinthera.2011.07.008. View

19.

Weiland O, HOLLANDER A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R . Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat. 2008; 15(9):641-5. DOI: 10.1111/j.1365-2893.2008.00999.x. View

20.

Yu M, Huang C, Huang J, Chang N, Yang J, Lin Z . Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology. 2011; 53(1):7-13. DOI: 10.1002/hep.23976. View